BioScrip (NASDAQ:BIOS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.
Several other equities analysts have also commented on the company. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. SunTrust Banks restated a “buy” rating and set a $3.25 price target on shares of BioScrip in a research note on Thursday, March 8th. Finally, Craig Hallum restated a “buy” rating and set a $3.50 price target on shares of BioScrip in a research note on Thursday, March 8th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $3.44.
Shares of BioScrip stock opened at $2.93 on Thursday. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. BioScrip has a 12 month low of $1.80 and a 12 month high of $3.39.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $168.60 million during the quarter, compared to analysts’ expectations of $164.72 million. The company’s revenue for the quarter was down 22.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.18) EPS. equities analysts forecast that BioScrip will post -0.31 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of BIOS. Gotham Asset Management LLC purchased a new position in BioScrip in the fourth quarter valued at about $114,000. MetLife Investment Advisors LLC purchased a new position in BioScrip in the fourth quarter valued at about $174,000. Two Sigma Advisers LP grew its stake in BioScrip by 100.4% in the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the last quarter. Wells Fargo & Company MN grew its stake in BioScrip by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock valued at $634,000 after purchasing an additional 55,636 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in BioScrip in the first quarter valued at about $635,000. Institutional investors own 85.46% of the company’s stock.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.